Insider share sale at current price, lack of insider buying, and insignificant insider ownership suggest caution before buying the stock, despite company's profitability and profit growth.
The company's consistent but low ROCE and the increase in capital employed without a corresponding increase in returns may be factors contributing to its relatively modest stock gain. The analysis suggests looking at other options for potential multi-baggers.
MMSI's shares are trading above fair value due to its positive outlook. Despite overvaluation, the company's expected higher cash flow could lead to a higher share valuation.
Merit Medical Systems' strong EPS growth is attractive to investors, as is the fact that insiders hold a substantial stake in the company. Because of this, further investigation into the company's true value is recommended.
The business isn't making high-return investments despite an increase in its capital employed. Even though Merit Medical Systems is increasing its capital, diminishing returns on said capital make it less attractive as a high-value growth stock.
The market sentiment looks positive as Merit Medical Systems turned profitable in the recent years. The company shows signs of improvement over time, with its gains better than the average annual return over the past five years.
The underpriced stock of Merit Medical Systems is a lucrative opportunity for investors, although a careful consideration of the company's financial health is advised. The future outlook for the company looks optimistic, yet this isn't entirely mirrored in its current share price. Don't forget to assess the company's balance sheet strength before investing.
The sales of shares by multiple insiders, including the founder, at prices close to the current stock price raises some concern. However, the 2.3% of the company owned by insiders indicates some level of alignment between management and smaller shareholders.
$Merit Medical Systems(MMSI.US)$5年来营收除2020年下滑3.1%以外增长了4年,平均增速为9.6%,营业利润则在2019年大幅下滑33.3%,之后连续增长3年,5年平均增速为17%,近两年平均增速48%,净利润则在2020年陷入亏损,近两年大幅增长至0.745亿。2020年亏损主要是资本性资产减值和其他特殊费用造成的,其余几年这个科目也一直不干净。 2023Q1营收增长8%,营业利润增长38%,净利润增长96%,净利润增速大幅高于毛利润主要是其他费用转变为其他收益的结果。 目前市盈率64,市盈率TTM降到了56,虽然相对于利润增速来说不高,但是高增速通常很难持久,可以多等待几个季度再说。
Merit Medical Systems股票讨论区
2023Q1营收增长8%,营业利润增长38%,净利润增长96%,净利润增速大幅高于毛利润主要是其他费用转变为其他收益的结果。
目前市盈率64,市盈率TTM降到了56,虽然相对于利润增速来说不高,但是高增速通常很难持久,可以多等待几个季度再说。
专栏Today's pre-market stock movers: F, META, BBY, QCOM and more
In reaction to earnings/guidance:
$Sunnova Energy International(NOVA.US)$ +13.6%,$Impinj(PI.US)$ +12%,$Etsy Inc(ETSY.US)$ +8.1%,$argenx SE(ARGX.US)$ +8.1%,$Netgear(NTGR.US)$ +6.9%,$福特汽车(F.US)$ +6.7%(also increases dividend),$Myovant Sciences(MYOV.US)$ +6%,$Merit Medical Systems(MMSI.US)$ +6%,$伊格尔矿业(AEM.US)$ +5.8%,$伟创力(FLEX.US)$ +5.1%,$MAA房产信托(MAA.US)$ +5%,$普雷克萨斯(PLXS.US)$ +5%,$哈雷戴维森(HOG.US)$ +5%,...
暂无评论